You are invited to participate as a juror in this dynamic, innovative program, where critical clinical issues across the spectrum of breast cancer care will be debated by International clinical experts and discussed by the faculty panel and attendees. Each faculty member will present their case and the participants will render judgments via the use of an audience response system. This interactive independent educational activity will provide medical oncologists, as well as allied healthcare professionals, who specialize in the care of patients with breast cancer with valuable insight in making optimal treatment decisions faced daily in clinical practice.

Target Audience
This educational activity is intended for medical, surgical, and radiation oncologists, as well as allied oncology healthcare professionals who treat patients with breast cancer.

Statement of Need
Significant improvements have occurred in the management of breast cancer over the past decade. One of the most widely studied approaches in the field of cancer, particularly breast cancer, is personalized treatment strategies incorporating gene array profiles, new agents and novel combinations. Despite these advances, uncertainties remain. With novel pharmacological agents, diagnostic and treatment strategies, the decision-making process is challenging, thereby requiring in-depth knowledge of current clinical and experimental data for the appropriate integration of new treatment strategies into clinical practice. Because of this, healthcare professionals caring for patients with breast cancer need to understand the basis for treatment approaches likely to change clinical practice in the next few years, as well as the preclinical and clinical data supporting the development and integration of these therapies into practice.

Educational Objectives
Upon completion of this educational activity, participants should be better able to:

• Distinguish currently available prognostic and predictive tools to guide in treatment management of breast cancer patients
• Describe rationale for the development and use of new therapeutic and individualized approaches to breast cancer
• Indicate the clinical implications of the results of pivotal clinical trials, including early phase trials, that have the potential to impact the use of therapies in breast cancer
• Identify potential treatment strategies and ongoing clinical trial designs for incorporating new treatment regimens in the treatment of breast cancer
• Cite data regarding the safety profiles of therapeutic approaches in the treatment of breast cancer, either alone or in combination with currently accepted standard therapies.
• Identify methods for side effect management and maintenance of quality of life
• Compare novel therapies and/or regimens that provide the best patient outcomes including whether current guidelines provide similar recommendations
• Compare clinical outcomes and endpoints in order to establish which clinical trials are the most meaningful in improving patient care
• Identify optimal treatment regimens for patients with resistant metastatic breast cancer and triple negative disease

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine (PIM) and PRIME Oncology. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
PIM designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
PIM assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM and PRIME Oncology for fair balance, scientific objectivity of studies utilized in this activity and patient care recommendations. PIM and PRIME Oncology are committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc).
Please contact Kim Friese prior to the live event at (678) 892-1340 or kim.friese@primeoncology.org.

Larry Norton, MD (Judge/Co-Chair)
Deputy Physician-in-Chief
Director
Breast Cancer Programs
Memorial Sloan-Kettering Cancer Center
New York, New York, USA


Martine Piccart-Gebhart, MD, PhD (Judge/Co-Chair)
Professor of Oncology
Universite Libre de Bruxelles
Director, Medicine Department
Institut Jules Bordet
Brussels, Belgium


Michael Untch, MD
Professor of Gynecology, Gynecologic Oncology
Director of Breast Cancer Center
HELIOS Klinikum Berlin-Buch
Berlin, Germany


José Baselga, MD
Professor of Medicine
Universidad Autonoma de Barcelona
Director, Division of Medical Oncology, Hematology,
and Radiation Oncology
Vall d’Hebron University Hospital
Barcelona, Spain


George W. Sledge, Jr, MD
Ballve-Lantero Professor of Medicine
Professor of Medicine and Pathology
Co-Director Breast Oncology Program
Chair, Breast Committee, Easter Cooperative Oncology Group
Indiana University Simon Cancer Center
Indianapolis, Indiana, USA


Hope Rugo, MD
Clinical Professor of Medicine
Division of Hematology & Oncology
Director, Breast Cancer Clinical Trials Program
University of California San Francisco
San Francisco, California, USA


Cliff Hudis, MD
Professor of Medicine
Weill Cornell College of Medicine
Chief, Breast Cancer Medicine Service
Memorial Sloan-Kettering Cancer Center
New York, New York, USA


William Gradishar, MD, FACP
Professor of Medicine
Director, Breast Medical Oncology
Program Director, Hematology/Oncology Fellowship
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, Illinois, USA


Nadia Harbeck, MD
Department of Obstetrics and Gynecology
Technical University of Munich
Munich, Germany


Lori Goldstein, MD
Director, Breast Evaluation Center
Director, Breast Cancer Research Program
Fox Chase Cancer Center
Philadelphia, Pennsylvania, USA

7:30 pm-7:40 pm	Registration and Dinner Welcome and Introduction Larry Norton, MD Martine Piccart-Gebhart, MD, PhD
Case #1
7:40 pm-8:05 pm	Management of Early Endocrine Responsive Postmenopausal Breast Cancer in the Near Future Will Include Upfront Extended Duration (>5 years) Adjuvant Aromatase Inhibitor Therapy and Adjuvant Use of a Bisphosphonate Pro: William Gradishar, MD, FACP Con: Nadia Harbeck, MD
Case #2
8:05 pm-8:30 pm	Optimal Treatment of Recurrent HER-2 Amplified Breast Cancer (One Year Following Adjuvant Trastuzumab) Should Be Rechallenge With Trastuzumab-based Therapy Pro: Cliff Hudis, MD Con: Michael Untch, MD
Case #3
8:30 pm-8:55 pm	Current Management of Triple Negative Breast Cancer Should Include Angiogenesis Inhibitor Pro: George Sledge, MD Con: José Baselga , MD
Case #4
8:55 pm-9:20 pm	Risk Assessment and Treatment Planning for a Small Endocrine Responsive Node Positive Early Breast Cancer Should Include a Gene Array Profile Analysis Pro: Lori Goldstein, MD Con: Hope Rugo, MD
9:20 pm-9:30 pm	“Judges” Closing Remarks and “Summation of Verdicts” Larry Norton, MD Martine Piccart-Gebhart, MD, PhD